Document is current
Any future updates will be listed below
-
Authors
de Rouw, N.
Beunders, R.
Hartmann, O.
Schulte, J.
Boosman, R. J.
Derijks, H. J.
Burger, D. M.
van den Heuvel, M. M.
Hilbrands, L. B.
Pickkers, P.
ter Heine, R.
-
Funding
Funding for this research was provided by:
ZonMW (848016010, 848016010, 848016010, 848016010, 848016010)
- License Information
-
More Information
Article History
Received: 20 July 2024
Accepted: 17 September 2024
First Online: 4 October 2024
Declarations
:
: NdR, RB, RB, HD, DB, LB, RtH: none. MvdH: Research funding: AstraZeneca, BMS, Janssen, Treatmeds, Merck, MSD, Novartis, Pfizer, Roche, Roche diagnostics Advisory/Speaker fees: Abbvie, AstraZeneca, BMS, Lilly, MSD, Novartis, Pfizer, Roche ther: SON-NVALT, NVALT-studies, Longkankernet. PP: received travel and consultancy reimbursements from Sphingotec. OH and JSc are employed by SphingoTec GmbH, the manufacturer of the PENK assay.
